Genetic Engineering & Biotechnology News

MAY15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/819033

Contents of this Issue

Navigation

Page 34 of 37

For more information, visit our website (GENengnews.com), click on New Products, and search through our comprehensive new products database. New Products Genetic Engineering & Biotechnology News | GENengnews.com | MAY 15, 2017 | 33 People XBiotech added the following members to its scientific advisory board: Thierry André, M.D., George A. Fisher Jr., M.D., Ph.D., Andrew Hendifar, M.D., Alexander Knuth, M.D., and Razelle Kurzrock, M.D. Perthera hired Doug Poretz as chief mar- keting officer; Steve Rivera as senior vice president of sales; David Halverson, M.D., as vice president and medical director; and Subha Madhavan, Ph.D., as chief bioinformatics officer. twoXAR formed a scientific advisory board consisting of Vijay Pande, Ph.D., Nigam Shah, Ph.D., and Mirana Sirota, Ph.D. Foresee Pharmaceuticals hired Yisheng Lee, M.D., Ph.D., as CMO; and David Lau, Ph.D., as senior vice president, NCE preclinical and clinical development. Q Med added Amy Ripka, Ph.D., and Rick Panicucci, Ph.D., to its scientific advisory board. Data MATRIX convened an advisory board, consisting of Philip Lavin and David Stein. Millendo Therapeutics appointed Mary Lynne Hedley, Ph.D., and Carole Nuechterlein, J.D., to its board of directors. Cellectar Biosciences elected Douglas Swirsky and Frederick Driscoll to its board of directors. Walter H. Moos, Ph.D., joined ShangPharma as CEO. Bio-Path hired William Hahne, M.D., as vice president of clinical development. Juno Therapeutics hired Sunil Agarwal, M.D., as president, R&D. Trovagene named Sandra Silberman, M.D., Ph.D., to its clinical advisory board. CytoDyn appointed Scott A. Kelly, M.D., to its board of directors. Rhythm elected David Meeker, M.D., chairman of its board of directors. Kevin Little, Ph.D., joined 3D Signatures as CSO. Taylor J. Crouch joined Organovo as CEO. Cellectar Biosciences hired John Friend II, M.D., as vice president and CMO. Retrophin appointed Ron Squarer to its board of directors. Mark Pegram, M.D., is the new scientific advisor at Esperance Pharmaceuticals. Agendia named Patrick J. Balthrop Sr. as nonexecutive chairman of its board of directors. John Mannick, M.D., is the new CMO at resTORbio. Merrimack hired Daryl Drummond, Ph.D., as head of research. Kevin Gorman, Ph.D., joined the board of directors at Xencor. Vir Biotechnology named George Poste, Ph.D., to its scientific advisory board. Biostage appointed Stephen F. Badylak, M.D., Ph.D., as co-chairman of its scientific advisory board. Yolanda Chong, Ph.D., is the new vice president of biology at Recursion Pharmaceuticals. Two Pore Guys welcomes Jordan Hubbard as vice president of engineering. Send your People Announcements to people@GENengnews.com Subscribe Clinical OMICs extends GEN's comprehensive coverage to the clinic by focusing on the application of revolutionary molecular technologies in medical practice. Topics covered include personalized and precision medicine, next-gen sequencing, bioinformatics, reimbursement, and bioethics. To see past issues, recent news, and subscribe, go to: clinicalomics.com GEN'S NEW ePUB Molecular Diagnostics in Personalized Medicine Advanced Analytical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Clinical OMICs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Cosmo Bio USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Florida Atlantic University . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 GEN/Corning webinar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 GEN/Icagen webinar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 IDEXX BioResearch . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Integra Biosciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Merck . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 MilliporeSigma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 OriGene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Panasonic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Qiagen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 25 RayBiotech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Roche Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Roche Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cover Tip Sonntek . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 ThermaGenix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Wacker Chemie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Ligand's OmniAb Platforms, Corporate Capability . . . . . . . . . . . . . . . . . . 30–31 William Sibold was promoted to executive vice president of Sanofi Genzyme. Sibold was the head of global MS, oncol- ogy, and immunology opera- tions. He joined Sanofi in 2011 as head of MS. Sibold began his career with Eli Lilly. He held several positions at Biogen, and was the chief commercial offi- cer at Avanir Pharmaceuticals. RXi Pharmaceuticals hired Gerrit Dispersyn, Dr. Med. Sc., as chief development officer. Dr. Dispersyn was most recently a vice president at Integra LifeSciences. Prior to that, he was a vice president at Barrier Therapeutics. Dr. Dispersyn is the founder of Ingress. Advertiser Index Tim Harris, Ph.D., joined Bioverativ as executive vice president, research and development. Previously, Dr. Harris was a venture partner at SV Life Sciences. Before that, he held several positions at Biogen. Profile Profile Profile Reprints Karen Ballen 914-740-2194 reprints@GENengnews.com GEN offers reprints of individual articles — in printed or electronic form — to increase awareness of your product or company. Order today! Classified - --

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - MAY15 2017